NCT07075120View on ClinicalTrials.gov

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

December 31, 2027

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

Ipilimumab and Nivolumab

Immunotherapy combination (Ipilimumab and Nivolumab) targeting CTLA-4 and PD-1 pathways to enhance immune response.

RADIATION

Stereotactic Body Radiotherapy (SBRT)

High-dose radiation therapy delivered in 3-5 fractions for local control of tumors in combination with immunotherapy. Radiation dosages are based on the RTOG 1112 trial guidelines to minimize normal tissue exposure.

Trial Locations (1)

96813

University of Hawai'i Cancer Center, Honolulu

All Listed Sponsors
lead

University of Hawaii

OTHER